NeuroVive's candidate for aiding in recovery after severe heart attacks failed to meet its endpoint following a topline analysis. "While the primary endpoint of the CIRCUS study has not been met, analysis of the full 12-month data set will provide us with more information in regard to which patients may have benefited from treatment with CicloMulsion. These results will help define next steps in the development and commercialization of CicloMulsion. The CIRCUS study is an independent, investigator-led study and we will continue to collaborate with the lead investigator to further evaluate the full 12-month study results as they become available," said NeuroVive CEO Mikael Brönnegård. CicloMulsion is a cremophor-free lipid emulsion formulation of cyclosporine. More